Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Remuneration Information 2013

Mar 5, 2013

4797_dirs_2013-03-05_a195e05b-168f-4407-8400-84844d80a6ac.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3112Z

Dechra Pharmaceuticals PLC

05 March 2013

5 March 2013

Dechra Pharmaceuticals PLC

(the "Company")

Director / PDMR Shareholding

The Company announces that the following Directors/PDMRs were today granted nil cost options over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the "Plan"):

Name of individual Director/PDMR Type of award Number of shares subject to award
Ian Page Director Option 94,420
Tony Griffin Director Option 34,401
Ed Torr Director Option 32,838
Zoe Goulding PDMR Option 17,167

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share ("EPS") and its Total Shareholder Return ("TSR") relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed ("ROCE") performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

For further information, please contact:

Zoe Goulding, Company Secretary            

Telephone number: 01782 771100

About Dechra

Dechra is an international veterinary pharmaceutical business.  Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSNKPDPABKDBNK